

**Study Number:** IMM20704

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Mouse/B6C3F1/N

**C Number:**

**Study Gender:**

**PWG Approval Date**

**I04: Mean Body Weight Summary**

**Test Compound:** Resveratrol

**CAS Number:** 501-36-0

IMM20704

Male

See web page for date of PWG Approval

**Date Report Requested:** 04/08/2020

**Time Report Requested:** 13:55:21

**Lab:** NTP

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 1**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0		156			312			625		
	Wt (g)	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.9 ± 0.8	8	27.2 ± 0.6	1.2	8	26.7 ± 0.8	-0.6	8	27.1 ± 0.7	0.7	8
SD8	26.6 ± 0.7	8	27.0 ± 0.7	1.4	8	26.3 ± 0.8	-1.2	8	26.5 ± 0.8	-0.6	8
SD15	27.7 ± 0.8	8	28.0 ± 0.8	0.9	8	28.5 ± 1.1	2.8	8	27.3 ± 0.8	-1.4	8
SD22	29.0 ± 0.9	8	29.1 ± 1.0	0.2	8	28.0 ± 1.1	-3.4	8	27.5 ± 0.8	-5.1	8
SD29	29.4 ± 0.8	8	29.0 ± 1.0	-1.4	8	28.4 ± 1.1	-3.4	8	28.1 ± 0.7	-4.4	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 1**

---

Phase Day	Treatment Groups (mg/kg/day)								
	1250			2500			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	27.2 ± 0.4	1.2	8	27.5 ± 0.7	2.3	8	28.9 ± 0.6	7.5	8
SD8	26.9 ± 0.4	0.8	8	26.7 ± 1.3	0.0	8	30.5 ± 0.6 **	14.6	8
SD15	25.8 ± 0.9	-6.9	8	27.1 ± 1.5	-2.4	8	32.9 ± 0.7 **	18.8	8
SD22	28.3 ± 0.7	-2.5	8	27.2 ± 1.7	-6.2	8	33.8 ± 0.8 **	16.5	8
SD29	27.5 ± 0.6	-6.4	7	29.3 ± 1.3	-0.3	7	33.0 ± 1.0 *	12.3	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 2**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0			156			312			625		
	Wt (g)	N		Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.6 ± 0.5	8		26.5 ± 0.5	-0.1	8	25.5 ± 0.6	-3.9	8	26.9 ± 0.5	1.4	8
SD8	27.2 ± 0.5	8		27.2 ± 0.5	-0.1	8	26.3 ± 0.6	-3.4	8	27.3 ± 0.5	0.4	8
SD15	27.0 ± 0.5	8		27.1 ± 0.7	0.3	8	26.4 ± 0.8	-2.3	8	27.5 ± 0.6	1.5	8
SD22	28.0 ± 0.7	8		27.8 ± 0.7	-1.0	8	27.4 ± 0.9	-2.5	8	28.2 ± 0.5	0.5	8
SD29	29.0 ± 0.7 **	8		28.8 ± 0.7	-0.6	8	28.2 ± 0.9	-2.8	8	29.0 ± 0.7	0.1	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 2**

---

Phase Day	Treatment Groups (mg/kg/day)								
	1250			2500			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.0 ± 0.6	-2.2	8	26.5 ± 0.4	-0.0	8	26.4 ± 0.5	-0.7	8
SD8	26.3 ± 0.4	-3.3	8	27.4 ± 0.5	0.7	8	27.2 ± 0.4	-0.1	8
SD15	26.2 ± 0.7	-3.0	8	25.5 ± 0.9	-5.7	8	28.3 ± 0.5	4.5	8
SD22	27.3 ± 0.6	-2.7	8	27.0 ± 0.8	-3.8	7	29.8 ± 0.7	6.4	8
SD29	27.0 ± 0.6	-7.0	8	26.6 ± 0.6 *	-8.4	7	28.0 ± 0.5	-3.5	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 3**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0		156			312			625		
	Wt (g)	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.7 ± 0.3	8	26.4 ± 0.5	-1.1	8	26.0 ± 0.5	-2.7	8	26.9 ± 0.5	0.6	8
SD8	27.3 ± 0.2	8	27.2 ± 0.5	-0.1	8	26.6 ± 0.4	-2.5	8	27.2 ± 0.6	-0.3	8
SD15	27.8 ± 0.2	8	28.0 ± 0.6	0.7	8	27.7 ± 0.4	-0.3	8	28.5 ± 0.7	2.6	8
SD22	28.6 ± 0.3	8	28.5 ± 0.7	-0.3	8	28.4 ± 0.4	-0.7	8	29.1 ± 0.7	1.6	8
SD29	29.2 ± 0.3	8	29.1 ± 0.6	-0.5	8	28.7 ± 0.6	-1.8	8	29.7 ± 0.8	1.6	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 3**

---

Phase Day	Treatment Groups (mg/kg/day)								
	1250			2500			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	27.3 ± 0.5	2.1	8	27.3 ± 0.5	2.2	8	26.8 ± 0.4	0.4	8
SD8	27.3 ± 0.6	0.0	8	27.2 ± 0.9	-0.2	8	27.3 ± 0.6	0.1	8
SD15	28.3 ± 0.9	2.0	7	27.3 ± 0.6	-1.6	8	29.5 ± 0.8	6.1	8
SD22	28.0 ± 0.4	-2.0	7	28.1 ± 0.7	-1.7	8	30.7 ± 0.9	7.4	8
SD29	29.7 ± 0.4	1.7	7	29.7 ± 0.6	1.8	8	30.1 ± 0.6	3.1	7

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 4**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0		156			312			625		
	Wt (g)	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	27.0 ± 0.6	8	27.7 ± 0.7	2.7	8	26.9 ± 0.5	-0.1	8	26.7 ± 0.4	-1.2	8
SD8	27.1 ± 0.6	8	28.0 ± 0.8	3.4	8	27.1 ± 0.6	0.1	8	27.1 ± 0.5	0.1	8
SD15	27.7 ± 0.7	8	28.6 ± 0.8	3.0	8	27.8 ± 0.6	0.2	8	27.6 ± 0.4	-0.6	8
SD22	28.7 ± 0.9	8	28.9 ± 0.9	0.8	8	28.1 ± 0.7	-2.2	8	27.7 ± 0.4	-3.5	8
SD29	29.5 ± 0.8	8	30.4 ± 1.0	3.3	8	29.7 ± 0.7	0.7	8	29.0 ± 0.4	-1.7	8



**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 4**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	1250			2500			50 mg/kg CPS			1:10 dilution AAGM1		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	27.0 ± 0.4	0.2	8	26.9 ± 0.4	-0.3	8	26.8 ± 0.4	-0.7	8	27.1 ± 0.5	0.6	8
SD8	27.0 ± 0.5	-0.3	8	26.4 ± 0.7	-2.4	7	27.2 ± 0.3	0.4	8	26.9 ± 0.5	-0.4	8
SD15	27.6 ± 0.5	-0.4	8	27.7 ± 0.5	-0.2	6	28.4 ± 0.3	2.2	7	27.8 ± 0.4	0.1	8
SD22	27.7 ± 0.6	-3.4	8	28.6 ± 1.1	-0.2	6	29.0 ± 0.4	1.0	8	28.7 ± 0.3	-0.0	8
SD29	28.6 ± 0.7	-3.1	8	29.0 ± 0.5	-1.5	6	28.7 ± 0.6	-2.5	8	29.9 ± 0.3	1.5	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 5**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0		156			312			625		
	Wt (g)	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.8 ± 0.7	8	26.9 ± 0.8	0.4	8	26.8 ± 0.5	-0.1	8	26.9 ± 0.3	0.5	8
SD8	27.0 ± 0.5	8	26.2 ± 0.8	-2.8	8	26.8 ± 0.5	-0.6	8	26.3 ± 0.4	-2.6	8
SD15	27.7 ± 0.6	8	27.1 ± 1.0	-2.3	8	27.8 ± 0.5	0.5	8	26.7 ± 0.4	-3.6	8
SD22	28.0 ± 0.6	8	27.8 ± 1.0	-1.0	8	28.3 ± 0.7	0.9	8	27.4 ± 0.5	-2.4	8
SD29	29.2 ± 0.6	8	28.6 ± 1.2	-2.2	8	29.2 ± 0.7	-0.3	8	27.7 ± 0.3	-5.2	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 5**

---

Phase Day	Treatment Groups (mg/kg/day)								
	1250			2500			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.9 ± 0.6	0.4	8	26.6 ± 0.4	-0.7	8	25.9 ± 0.5	-3.2	8
SD8	26.4 ± 0.6	-2.0	8	26.8 ± 0.5	-0.8	8	25.7 ± 0.4	-4.8	8
SD15	27.2 ± 0.4	-1.9	8	26.9 ± 0.6	-2.9	8	26.5 ± 0.7	-4.2	8
SD22	27.8 ± 0.5	-0.9	8	27.4 ± 0.7	-2.1	8	27.9 ± 0.6	-0.5	8
SD29	28.2 ± 0.7	-3.5	8	28.3 ± 0.4	-3.3	8	27.9 ± 0.5	-4.5	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 6**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0			156			312			625		
	Wt (g)	N		Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.9 ± 0.5	8		26.4 ± 0.4	-1.9	8	25.9 ± 0.4	-3.8	8	26.2 ± 0.3	-2.7	8
SD8	26.7 ± 0.7	8		27.2 ± 0.4	1.6	8	26.3 ± 0.4	-1.8	8	26.9 ± 0.4	0.6	8
SD15	28.1 ± 0.3	8		28.2 ± 0.5	0.2	8	27.0 ± 0.3	-4.0	8	27.2 ± 0.6	-3.1	8
SD22	29.0 ± 0.3	8		29.0 ± 0.6	-0.0	8	27.8 ± 0.5	-4.2	8	28.6 ± 0.5	-1.4	8
SD29	29.0 ± 0.4	8		28.5 ± 0.5	-1.6	8	27.8 ± 0.4	-3.9	8	28.4 ± 0.5	-2.1	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 6**

---

Phase Day	Treatment Groups (mg/kg/day)								
	1250			2500			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	26.1 ± 0.5	-3.0	8	26.3 ± 0.4	-2.1	8	26.2 ± 0.5	-2.5	8
SD8	26.4 ± 0.5	-1.4	8	27.1 ± 0.5	1.5	7	26.9 ± 0.7	0.6	8
SD15	27.3 ± 0.7	-2.8	8	27.7 ± 0.8	-1.6	7	28.7 ± 0.8	1.9	8
SD22	28.3 ± 0.8	-2.2	8	28.5 ± 1.4	-1.6	7	30.2 ± 1.1	4.4	8
SD29	28.0 ± 0.8	-3.2	8	29.3 ± 0.7	1.2	6	28.8 ± 1.0	-0.5	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 7**

---

**Treatment Groups (mg/kg/day)**

---

Phase Day	0		156			312			625		
	Wt (g)	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	28.2 ± 0.5	8	27.7 ± 0.6	-1.6	8	26.8 ± 0.3	-4.8	8	28.1 ± 0.5	-0.3	8
SD8	28.8 ± 0.4	8	28.5 ± 0.4	-1.1	8	27.8 ± 0.4	-3.5	8	28.5 ± 0.6	-1.0	8
SD15	29.4 ± 0.5	8	28.9 ± 0.4	-1.7	8	28.2 ± 0.4	-3.9	8	28.8 ± 0.7	-2.0	8
SD22	30.0 ± 0.6	8	29.5 ± 0.5	-1.5	8	27.9 ± 0.5	-6.8	8	29.2 ± 0.7	-2.4	8
SD29	31.0 ± 0.7	8	30.3 ± 0.5	-2.1	8	29.0 ± 0.4	-6.3	8	30.4 ± 0.8	-1.8	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

---

**Males: Study 7**

---

Phase Day	Treatment Groups (mg/kg/day)								
	1250			2500			50 mg/kg MVE		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD1	27.8 ± 0.7	-1.3	8	27.7 ± 0.5	-1.7	8	27.5 ± 0.4	-2.3	8
SD8	28.6 ± 0.6	-0.5	8	29.0 ± 0.5	0.7	8	28.9 ± 0.5	0.5	8
SD15	29.0 ± 0.4	-1.2	8	29.1 ± 0.5	-1.0	8	30.0 ± 0.6	2.3	8
SD22	29.6 ± 0.5	-1.2	8	29.6 ± 0.5	-1.0	7	30.7 ± 0.8	2.5	8
SD29	30.6 ± 0.5	-1.1	8	30.0 ± 0.8	-3.1	7	31.4 ± 0.9	1.3	8

**Study Number:** IMM20704  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Mouse/B6C3F1/N

**I04: Mean Body Weight Summary**  
**Test Compound:** Resveratrol  
**CAS Number:** 501-36-0

**Date Report Requested:** 04/08/2020  
**Time Report Requested:** 13:55:21  
**Lab:** NTP

#### LEGEND

---

Data are displayed as mean  $\pm$  SEM

SD – Study Day

Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

Change in N for Study 4 for study day 15 in the 50 mg/kg CPS group is due to one animal's body weight being excluded as an outlier.

CPS = Cyclophosphamide

AAGM1 = Anti-Asialo GM1 (Rabbit) Antibody

MVE = Maleic Vinyl Ether

**\*\* END OF REPORT \*\***